Cervical CancerROCCNCT04831580
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
A study testing da Vinci and open surgery in people with Cervical Cancer, run by GOG Foundation at 156 sites in 4 countries.
Trial summary
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Cervical Cancer
- What is being tested?
- da Vinci and open surgery
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 840 participants
- Where
- 156 sitesin 4 countries
- Study dates
- 22 Mar 2022to Mar 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must have histologically confirmed adenocarcinoma (usual/classic/NOS), squamous cell carcinoma, adenosquamous carcinoma (Including glassy cell)
- Patient must be FIGO Stage IA2, IBI, IB2 (2018 staging) without evidence of definitive parametrial, vaginal, nodal or distant metastases on exam or imaging. Patients with tumor size less than or equal to 4 cm confirmed on MRI prior to randomization are eligible.
- Patient must have uterine size <12 cm AND felt to be appropriate for vaginal delivery of the specimen per investigator.
- Patient must be suitable surgical candidate with preoperative assessments such as labs and EKG performed per institutional standard and agree to be randomized to undergo open or robotic radical (or simple) hysterectomy.
- NOTE: Simple hysterectomy will be allowed in patients who meet the following criteria:
- pelvic MRI must demonstrate a maximal tumor size of 2 cm or less AND
Show all 12Show fewer
- less than 50% stromal invasion on MRI if tumor present or less than 10 mm of stromal invasion if an excisional (cold knife or LEEP) has been performed.
- Submission of source documents in the GOG Partners Source Document Portal will be required prior to randomization for review and confirmation of simple hysterectomy being met (see Section 6.0 for instructions).
- Patient must be age 18 years or older.
- Patient must have ECOG performance status 0-1.
- Patient must have a negative urine pregnancy test within 30 days of surgery in pre-menopausal women.
- Patient must have signed an approved informed consent and authorization permitting the release of personal health information.
Who cannot join
- Patients with any tumor histology other than those listed above, specifically excluding the following histologies: neuroendocrine, other adenocarcinoma (gastric type, endometrioid, clear cell, serous, signet ring, minimal deviation)
- Patients with FIGO stage 1A1, IB3, II-IV (2018 staging).
- Patient with inability to receive an MRI.
- Patients with a tumor size greater than 4cm or on MRI confirmed prior to randomization are excluded. Patients with definite evidence of vaginal/parametrial involvement on MRI are excluded; if MRI findings are not definitive, then clinical examination must also not reveal parametrial or vaginal extension).
- Patients with evidence of metastatic disease (imaging or histologically positive lymph nodes).
- Patients with a history of prior pelvic or abdominal radiotherapy.
Show all 10Show fewer
- Patients with a prior malignancy < 5 years from enrollment with the exception of non-melanoma skin cancer.
- Patients who are unable to withstand prolonged lithotomy or steep trendelenberg.
- Patient compliance and geographic proximity that do not allow adequate follow-up.
- Patients with poorly controlled HIV with CD4 counts <500.
Trial locations and contacts
156 sites in 4 countries. Contact the study team or a site near you to ask about taking part.
156 sites in 4 countries
United States137 sites, 117 recruiting
- Recruiting
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Ashley Douglas, ashley.douglas@jefferson.edu
Mitchell Edelson, MD
- Recruiting
Summa Health Jean and Milton Copper Pavilion
Akron, Ohio, 44304
Danielle McCutcheon, mccutcheond@summahealth.org
Clarissa Polen, MD
- Recruiting
Summa Health Jean and Milton Copper Pavillion
Akron, Ohio, 44304
Danielle McCutcheon, mamccutcheond@summahealth.org
Clarissa De-Polen, MD
- Active, not recruiting
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, 87131
- Recruiting
Georgian Cancer Center at Augusta University
Augusta, Georgia, 30912
Angela Goebel, agoebel@augusta.edu
Sharad Ghamande, MD
- Recruiting
Texas Oncology-Austin
Austin, Texas, 78758
Kelli Watkins, kelli.watkins@mckesson.com
Helen Eshed, MD
- Recruiting
Memorial Sloan Kettering (Basking Ridge)
Basking Ridge, New Jersey, 07920
Josie Anderson, andersj@mskcc.org
Mario Leitao, MD
- Recruiting
Northwell Health/South Shore University Hospital
Bay Shore, New York, 11706
Batool Mubashar, mailto:bmubashar@northwell.edu
Jill Whyte, MD
- Recruiting
Texas Oncology- GYN ONC DFWW
Bedford, Texas, 76022
Nori Sullivan, mailto:nori.sullivan@usoncology.com
Noelle Cloven, MD
- Recruiting
Texas Oncology-DFWW
Bedford, Texas, 76022
Sarah Wade, mailto:Sarah.Wade@usoncology.com
Mark Messing, MD
- Recruiting
Northwell Health Physician Partners/Gynecological Oncology at Brightwaters
Brightwaters, New York, 11718
Batool Mubashar, mailto:bmubashar@northwell.edu
Jill Whyte, MD
- Recruiting
Laura and Issac Perlmutter Cancer Center at NYU Langone
Brooklyn, New York, 11220
Kathryn Allen, mailto:Kathryn.Allen@nyulangone.org
Whitfield Growdon, MD
- Recruiting
NYU Langone Ambulatory Care Bay Ridge
Brooklyn, New York, 11220
Kathryn Allen, mailto:Kathryn.Allen@nyulangone.org
Whitfield Growdon, MD
- Recruiting
NYU Langone Hospital-Brooklym
Brooklyn, New York, 11220
Kathryn Allen, mailto:Kathryn.Allen@nyulangone.org
Whitfield Growdon, MD
- Recruiting
Novant Health Cancer Institute
Charlotte, North Carolina, 28204
Kunal Shah
kashah@novanthealth.org
- Recruiting
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903
Rachel Lacy, mrmc9p@hscmail.mcc.virginia.edu
Leigh Cantrell, MD
- Recruiting
University of Virginia
Charlottesville, Virginia, 22903
Rachel Lacy, rmc9p@hscmail.mcc.virginia.edu
Leigh Cantrell, MD
- Recruiting
Chattanooga's Program in Women's Oncology
Chattanooga, Tennessee, 37403
Kimberly Donelson, Kimberly.Donelson@erlanger.org
Stephen Depasquale, MD
- Active, not recruiting
TriHealth Cancer Institute-Good Samaritan Hospital
Cincinnati, Ohio, 45220
- Active, not recruiting
TriHealth Cancer Institute-Thomas Comprehensive Care Center
Cincinnati, Ohio, 45220
- Recruiting
University of Cleveland Medical Center
Cleveland, Ohio, 44106
Lauren Patrick, Lauren.Patrick@uhhospitals.org
Lindsey Ferguson, MD
- Recruiting
OSU Wexner Medical Center Hospital East
Columbus, Ohio, 43203
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
OSU Wexner Medical Center Outpatient Care East
Columbus, Ohio, 43203
Callan Myserscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
James Cancer Hospital & Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Callan Myercough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
OSU Wexner Medical Center University Hospital
Columbus, Ohio, 43210
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
OSU Wexner Medical Center Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio, 43212
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
OSU Wexner Medical Center Martha Morehouse Outpatient Care
Columbus, Ohio, 43221
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
OSU Wexner Medical Center Outpatient Care Upper Arlington
Columbus, Ohio, 43221
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
OSU Wexner Medical Center Outpatient Care Gahanna
Columbus, Ohio, 43230
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
Memorial Sloan Kettering (Commack)
Commack, New York, 11725
Josie Anderson, andersj@mskcc.org
Mario Leitao, MD
- Recruiting
Texas Oncology- Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246
Christine Terraciano, 214-370-1000, christine.terraciano@usoncology.com
Brandon Sawyer, MD
- Recruiting
University of Texas Southwestern Medical Center-Simmons Cancer Center
Dallas, Texas, 75390
Annette Paulsen, mailto:Annette.Paulsen@UTSouthwestern.edu
Elizabeth Stock, MD
- Recruiting
University of Texas Southwestern Medical Center-WIlliam P. Clements Jr. University Hospital
Dallas, Texas, 75390
Annette Paulsen, Annette.Paulsen@UTSouthwestern.edu
Elizabeth Stock, MD
- Recruiting
University of Texas Southwestern Medical Center-Zale Lipshy University Hospital
Dallas, Texas, 75390
Annette Paulsen, Annette.Paulsen@UTSouthwestern.edu
Elizabeth Stock, MD
- Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
Annette Paulsen, mailto:Annette.Paulsen@UTSouthwestern.edu
Elizabeth Stock, MD
- Recruiting
City of Hope
Duarte, California, 91010
Raechelle Tinsley, RTinsley@coh.org
Mihae Song, MD
- Recruiting
OSU Wexner Medical Center Outpatient Care Dublin
Dublin, Ohio, 43016
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
Duke University Hospital
Durham, North Carolina, 27705
Taylor Hayes, taylor.hayes@duke.edu
Emma Rossi, MD
- Recruiting
Duke Cancer Center
Durham, North Carolina, 27710
Taylor Hayes, taylor.hayes@duke.edu
Emma Rossi, MD
- Recruiting
Duke Cancer Center
Durham, North Carolina, 27710
Lauren March, lauren.march@duke.edu
Emma Rossi, MD
- Active, not recruiting
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017
- Recruiting
University of California San Diego Medical Center
Encinitas, California, 92024
Alexandrea Cronin
aocronin@health.ucsd.edu
- Recruiting
Inova Health System
Fairfax, Virginia, 22031
Takada Harris, takada.harris@inova.org
Leslie Randall, MD
- Recruiting
Texas Oncology-GYN ONC DFWW
Fort Worth, Texas, 76104
Nori Sullivan, mailto:nori.sullivan@usoncology.com
Noelle Cloven, MD
- Recruiting
Texas Oncology
Fort Worth, Texas, 76104
Nori Sullivan, mailto:nori.sullivan@usoncology.com
Noelle Cloven, MD
- Recruiting
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee, 38119
Joslyn Walker, 901-683-0055, jowalker@westclinic.com
Todd Tillmanns, MD
- Withdrawn
Western Regional Medical Center LLC
Goodyear, Arizona, 85338
- Recruiting
Novant Health Cancer Institute
Greensboro, North Carolina, 27403
Kunal Shah
kashah@novanthealth.org
- Recruiting
Memorial Sloan Kettering (Westchester)
Harrison, New York, 10604
Josie Anderson, andersj@mskcc.org
Mario Leitao, MD
- Recruiting
Hartford Hospital
Hartford, Connecticut, 06102
Siobhan Reilly, mailto:siobhan.reilly@hhchealth.org
Johathan Cosin, MD
- Recruiting
Hartford Healthcare Cancer Institute at Hartford Hospital
Hartford, Connecticut, 06106
Siobhan Reilly, mailto:siobhan.reilly@hhchealth.org
Johathan Cosin, MD
- Recruiting
VCU Health at GreenGate
Henrico, Virginia, 23233
Sonya Washington, slwashington@vcu.edu
Chelsea Salyer, MD
- Recruiting
JamesCare Gynecologic Oncology at Mill Run
Hilliard, Ohio, 43026
Callan Myerscough, macallan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
Northwell Health/Huntington Hospital
Huntington, New York, 11743
Batool Mubashar, mailto:bmubashar@northwell.edu
Jill Whyte, MD
- Withdrawn
St. Vincent Hospital and Health Care Center Inc
Indianapolis, Indiana, 46260
- Withdrawn
St. Vincent Hospital and Health Care Center, Inc
Indianapolis, Indiana, 46260
- Recruiting
City of Hope Orange County Lennar Foundation Cancer
Irvine, California, 92618
Raechelle Tinsley, rtinsley@coh.org
Mihae Song, MD
- Recruiting
Ascension Medical Group St. Vincent's Obstetrics and Gynecology
Jacksonville, Florida, 32204
Nicole Antenucci, nicole.antenucci@ascension.org
Martin Martino, MD
- Recruiting
Novant Health Cancer Institute
Kernersville, North Carolina, 27284
Kunal Shah
kashah@novanthealth.org
- Recruiting
Kettering Health Cancer Center
Kettering, Ohio, 45429
Julie Carstens, julie.carstens@ketteringhealth.org
Thomas Reid, MD
- Recruiting
University of California San Diego Medical Center
La Jolla, California, 92037
Alexandrea Cronin
aocronin@health.ucsd.edu
- Recruiting
University of California San Diego Moores Cancer Center
La Jolla, California, 92093
Alexandrea Cronin
aocronin@health.ucsd.edu
- Recruiting
OSU Wexner Medical Center Outpatient Care Lewis Center
Lewis Center, Ohio, 43035
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
Baptist Health Lexington
Lexington, Kentucky, 40503
Lauren Higgins, lauren.higgins@bhsi.com
Hope Cottrill, MD
- Recruiting
Baptist Health
Lexington, Kentucky, 40503
Lauren Higgins, lauren.higgins@bhsi.com
Hope Cottrill, MD
- Recruiting
UCLA Gynecologic Oncology Clinic
Los Angeles, California, 90095
Dana Chase, MD, dmchase@mednet.ucla.edu
Dana Chase, MD
- Recruiting
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792
Claire Kostechka, kostechka@wisc.edu
Stephen Rose, MD
- Recruiting
Hartford Healthcare Medical Group-Manchester
Manchester, Connecticut, 06042
Siobhan Reilly, mailto:siobhan.reilly@hhchealth.org
Johathan Cosin, MD
- Recruiting
Mercy Hospital
Miami, Florida, 33133
Jennifer Mosley, Jennifer.mosley@hcahealthcare.com
Ricardo Estape, MD
- Withdrawn
Mount Sinai Comprehensive Cancer Center
Miami, Florida, 33140
- Recruiting
South Miami Hospital
Miami, Florida, 33143
Jacqueline Lebron, jacquelile@baptisthealth.net
John P Diaz, MD
- Recruiting
South Miami Hospital
Miami, Florida, 33143
Stephany Fuentes Angulo, Stephany.FuentesAngulo@baptisthealth.net
John Diaz, MD
- Recruiting
Mercy Hospital
Miami, Florida, 33173
Jennifer Mosley, Jennifer.mosley@hcahealthcare.com
Ricardo Estape, MD
- Recruiting
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176
Jacqueline Lebron, jacquelile@baptisthealth.net
John P Diaz, MD
- Recruiting
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176
Stephany Fuentes Angulo, Stephany.FuentesAngulo@baptisthealth.net
John Diaz, MD
- Recruiting
Memorial Sloan Kettering (Monmouth)
Middletown, New York, 07748
Josie Anderson, andersj@mskcc.org
Mario Leitao, MD
- Recruiting
Minnesota Oncology Hematology
Minneapolis, Minnesota, 55404
Jessica Thomes-Pepin, jessica.thomespepin@usoncology.com
Jessica Thomes-Pepin, MD
- Recruiting
M Health Fairview University of Minnesota Medical Center-East Bank Hospital
Minneapolis, Minnesota, 55455
Erin Zielinksi, eezielin@umn.edu
Colleen Rivard, MD
- Recruiting
M Health Fairview University of Minnesota Medical Center-East Bank Hospital
Minneapolis, Minnesota, 55455
Erin Zielinksi, eezielin@umn.edu
Collen Rivard, MD
- Recruiting
Memorial Sloan Kettering (Bergen)
Montvale, New Jersey, 07645
Josie Anderson, andersj@mskcc.org
Mario Leitao, MD
- Recruiting
West Virginia University
Morgantown, West Virginia, 26506
Christina Martinelli, mailto:christina.martinelli@hsc.wvu.edu
Krista Phaendler, MD
- Recruiting
West Virginia
Morgantown, West Virginia, 26506
Christina Martinelli, mailto:christina.martinelli@hsc.wvu.edu
Krista Pfaendler, MD
- Recruiting
Novant Health Cancer Institute
Mount Airy, North Carolina, 27030
Kunal Shah
kashah@novanthealth.org
- Recruiting
Harford HealthCare Cancer Institute at the Hospital of Central Connecticut
New Britain, Connecticut, 06053
Siobhan Reilly, mailto:siobhan.reilly@hhchealth.org
Johathan Cosin, MD
- Recruiting
Northwell Health/Long Island Jewish Medical Center
New Hyde Park, New York, 11040
Batool Mubashar, mailto:bmubashar@northwell.edu
Jill Whyte, MD
- Recruiting
NHPP/Gynecologic Oncology at New Hyde Park
New Hyde Park, New York, 11042
Batool Mubashar, mailto:bmubashar@northwell.edu
Jill Whyte, MD
- Recruiting
LSU Health New Orleans
New Orleans, Louisiana, 70112
Dina Brackman, dbrack@lsuhsc.edu
Amelia Jernigan, MD
- Recruiting
Laura and Issac Perlmutter Cancer Center at NYU Langone-East 34th Street
New York, New York, 10016
Kathryn Allen, mailto:Kathryn.Allen@nyulangone.org
Whitfield Growdon, MD
- Recruiting
Laura and Issac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016
Kathryn Allen, mailto:Kathryn.Allen@nyulangone.org
Whitfield Growdon, MD
- Recruiting
NYU Langone Medical Center (Tisch Hospital)
New York, New York, 10016
Kathryn Allen, mailto:Kathryn.Allen@nyulangone.org
Whitfield Growdon, MD
- Recruiting
The Blavatnik Family - Chelsea Medical Center at Mount Sinai
New York, New York, 10029
Neha Kumarley, 212-824-7859, Kuneha.kumarley@mssm.edu
Kristen P Zeligs, MD
- Recruiting
Josie Robertson Surgery Center
New York, New York, 10065
Josie Anderson, andersj@mskcc.org
Mario Leitao, MD
- Recruiting
Memorial Sloan Kettering Cancer Center (Main Campus)
New York, New York, 10065
Josie Anderson, mailto:andersj@mskcc.org
Mario Leitao, MD
- Withdrawn
Southeastern Regional Medical Center LLC
Newnan, Georgia, 30265
- Recruiting
Hoag Gynecologic Oncology
Newport Beach, California, 92633
Ana Navarrete, ana.navarrete@hoag.org
Alberto Meddivil, MD
- Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663
Ana Navarrete, ana.navarrete@hoag.org
Alberto Mendivil, MD
- Recruiting
Novant Health Cancer Institute
North Wilkesboro, North Carolina, 28659
Kunal Shah
kashah@novanthealth.org
- Recruiting
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104
Morgan Hays, mailto:morgan-hays@ouhsc.edu
Joan Walker, MD
- Withdrawn
Orlando Health Cancer Center
Orlando, Florida, 32806
- Withdrawn
Orlando Health Winnie Palmer Hospital for Woman and Babies
Orlando, Florida, 32806
- Withdrawn
Palo Alto Medical Foundation
Palo Alto, California, 94040
- Recruiting
Stanford Hospital
Palo Alto, California, 94305
Samya Konda, skonda@stanford.edu
Amer K Karam, MD
- Recruiting
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104
Christine Yang, christine.yang@pennmedicine.upenn.edu
Nawr Latif, MD
- Withdrawn
FirstHealth Outpatient Cancer Center
Pinehurst, North Carolina, 28374
- Recruiting
Magee - Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213
Jessica Yauch, yauchj@upmc.edu
Alexander Olawaiye, MD
- Recruiting
AHN West Penn Hospital
Pittsburgh, Pennsylvania, 15224
Janke Mains- Mason
janke.mainsmason@ahn.org
- Withdrawn
Legacy Good Samaritan Medical Center-Gynecological Oncology Group
Portland, Oregon, 97210
- Recruiting
Providence Center Institute Franz Clinic
Portland, Oregon, 97213
Nora Auston, Nora.Auston@providence.org
Christopher Darus, MD
- Recruiting
Women's and Infants Hospital of Rhode Island Program in Women's Oncology
Providence, Rhode Island, 02905
Ann John, ajohn@wihri.org
Elizabeth Lokich, MD
- Recruiting
VCU Health Emergency Center at New Kent
Quinton, Virginia, 23141
Sonya Washington, mailto:slwashington@vcu.edu
Chelsea Salyer, MD
- Recruiting
Center of Hope
Reno, Nevada, 89511
Shannon White Pierpoint, spierpoint@cohreno.com
Peter Lim, MD
- Recruiting
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, 23219
Sonya Washington, mailto:slwashington@vcu.edu
Chelsea Salyer, MD
- Recruiting
VCU Health Short Pump Pavillion
Richmond, Virginia, 23233
Sonya Washington, mailto:slwashington@vcu.edu
Chelsea Salyer, MD
- Recruiting
VCU Massey Cancer Center at Stony Point
Richmond, Virginia, 23235
Sonya Washington, mailto:slwashington@vcu.edu
Chelsea Salyer, MD
- Recruiting
Virginia Commonwealth University-Main Hospital
Richmond, Virginia, 23298
Sonya Washington, mailto:slwashington@vcu.edu
Chelsea Salyer, MD
- Recruiting
Texas Oncology-San Antonio
San Antonio, Texas, 78240
Riquanda Walker, Riquanda.Walker@McKesson.com
Joseph de la Garza, MD
- Recruiting
University of California San Diego Medical Center
San Diego, California, 92103
Alexandrea Cronin
aocronin@health.ucsd.edu
- Withdrawn
California Pacific Medical Center-Research Institute
San Francisco, California, 91409
- Recruiting
Maine Medical Partners-Woman's Health-Division of Gynecologic Oncology
Scarborough, Maine, 04074
Robin Donovan, donovr@mmc.org
Leslie Bradford, MD
- Recruiting
Willis-Knighton Physician Network Gynecologic Oncology Associates
Shreveport, Louisiana, 71118
Carrie Key, RN, ckay@wkhs.com
Destin Black, MD
- Withdrawn
Baystate Medical Center
Springfield, Massachusetts, 01199
- Recruiting
David C. Pratt Center
St Louis, Missouri, 63141
Crystal Tindall, crystal.tindall@mercy.net
Erica Huelsmann, MD
- Recruiting
Novant Health Cancer Institute
Statesville, North Carolina, 28625
Kunal Shah
kashah@novanthealth.org
- Withdrawn
Tampa General Hospital
Tampa, Florida, 33606
- Active, not recruiting
VCU Health at Tappahannock Hospital
Tappahannock, Virginia, 25560
- Recruiting
Texas Oncology-The Woodlands, Gynecologic Oncology
The Woodlands, Texas, 77380
Kelli Watkins, Kelli.Watkins@mckesson.com
Christine Lee, MD
- Recruiting
Novant Health Cancer Institute
Thomasville, North Carolina, 27360
Kunal Shah
kashah@novanthealth.org
- Withdrawn
Legacy Meridian Park Medical Center-Legacy Medical Gynecologic Oncology
Tualatin, Oregon, 97062
- Recruiting
Memorial Sloan Kettering (Nassau)
Uniondale, New York, 11553
Josie Anderson, andersj@mskcc.org
Mario Leitao, MD
- Recruiting
City of Hope - Upland
Upland, California, 91786
Raechelle Tinsley, rtinsley@coh.org
Mihae Song, MD
- Withdrawn
Legacy Salmon Creek Medical Center-Legacy Medical Group Gynecologic Oncology
Vancouver, Washington, 98686
- Recruiting
University of California San Diego Medical Center
Vista, California, 92081
Alexandrea Cronin
aocronin@health.ucsd.edu
- Recruiting
OSU Wexner Medical Center Outpatient Care New Albany
Westerville, Ohio, 43081
Callan Myerscough, callan.myerscough@osumc.edu
Floor Backes, MD
- Recruiting
VCU Health-William and Mary
Williamsburg, Virginia, 23185
Sonya Washington, mailto:slwashington@vcu.edu
Chelsea Salyer, MD
- Recruiting
Asplundh Cancer Pavillion
Willow Grove, Pennsylvania, 19090
Ashley Douglas, ashley.douglas@jefferson.edu
Mitchell Edelson, MD
- Recruiting
Novant Health Cancer Institute
Winston-Salem, North Carolina, 27103
Kunal Shah
kashah@novanthealth.org
- Recruiting
Alliance Cancer Specialists, PC
Wynnewood, Pennsylvania, 19096
Mark Shahin, MD, mark.shahin@usoncology.com
Mark Shahin, MD
South Korea10 sites, 10 recruiting
- Recruiting
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, 13496
Hyun Park, MD, p06162006@cha.ac.kr
Hyun Park, MD
- Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620
Dong Hoon Suh, MD, sdhwcj@naver.com
Dong Hoon Suh, MD
- Recruiting
Gangnam Severance Hospital
Seoul, Republic of Korea, 06273
JaeHoon Kim, jaehoonkim@yuhs.ac
HyunJin Lee, pistis@yuhs.ac
- Recruiting
Severance Hospital - Yonsei Cancer Center
Seoul, Republic of Korea, 07722
Ji Won, Woo, te05028@yuhs.ac
Sang-wun Kim, MD, PhD, san1@yuhs.ac
- Recruiting
Korea University Guro Hospital
Seoul, Republic of Korea, 08308
Sohyeon Jeong, MD, shj9918@gmail.com
Sohyeon Jeong, MD
- Recruiting
Korea University Anam Hospital
Seoul, 02843
Jae-Yun Song, MD, sjyuni105@gmail.com
Jae-Yun Song, MD
- Recruiting
Asan Medical Center
Seoul, 05505
Dae Yeon Kim, MD, kdyog@amc.seoul.kr
Dae Yeon Kim, MD
- Recruiting
Samsung Medical Center
Seoul, 06351
Chel Hun Choi, PhD, chelhun.choi@samsung.com
Chel Hun Choi, PhD
- Recruiting
Seoul St. Mary's Hospital - Catholic University
Seoul, 06591
Sung Jong Lee, MD, orlando@catholic.ac.kr
Sung Jong Lee, MD
- Recruiting
Severance Hospital - Yonsei Cancer Center
Seoul, 07722
Sangwun Kim, MD, san1@yuhs.ac
Sangwun Kim, MD
Brazil6 sites, 6 recruiting
- Recruiting
Barretos Cancer Hospital
Barretos, São Paulo, 14784-400
Daniela Augustin, daniela.augustin@lacogcancerresearch.org
Ricardo dos Reis, PhD
- Recruiting
Hospital Erasto Gaertner
Curitiba, Paraná, 81520-060
Erik M Coelho, erik.coelho@lacog.group
Audrey Tsunoda, MD, atsunoda@gmail.com
- Recruiting
Brazilian National Cancer Institute
Rio de Janeiro, 20081-250
Gustavo Guitmann, PhD, Guitmann@clinicagincol.com.br
Gustavo Guitmann, PhD
- Recruiting
Hospital de Base - Fundacao Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, São Paulo, 15090-000
Carlos E Andrade, MD, mdcarlosandrade@gmail.com
Erik Coelho, erik.coelho@lacog.group
- Recruiting
Hospital Municipal Vila Santa Catarina
São Paulo, Sao Paula, 04378-500
Renato Moretti-Marques, MD, renato.moretti@einstein.br
Renato Moretti-Marques, MD
- Recruiting
A.C.Camargo Cancer Center
São Paulo, São Paulo, 01509001
Daniela Augustin, daniela.augustin@lacogcancerresearch.org
Glauco Baiocchi Neto, PhD
Canada3 sites, 3 recruiting
- Recruiting
McGill University Health Centre-Glen Site
Montreal, Quebec, H4A 3J1
Phuong-Nam Nguyen, mailto:phuong-nam.nguyen@mail.mcgill.ca
Xing Zeng, MD
- Recruiting
Centre Hospitalier De L'Universite De Montreal
Montreal, H2X 3E4
Mathilde Duplaix, mathilde.duplaix.chum@ssss.gouv.qc.ca
Vanessa Samouelian, MD
- Recruiting
Princess Margaret Cancer Center
Toronto, Ontario, M5G2M9
Vanessa Ballin, Vanessa.Ballin@uhn.ca
Sarah Ferguson, MD, sarah.ferguson@uhn.ca
About this study
Official title: A Randomized Controlled Trial of Robotic Versus Open Surgery for Early Stage Cervical Cancer (ROCC)
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Read the detailed description
This is a multi-center, open-label, randomized, non-inferiority clinical trial with the hypothesis that robotically assisted hysterectomy with tumor containment prior to colpotomy is non-inferior to abdominal hysterectomy with respect to disease free survival.
At the commencement of surgery, a thorough inspection of all peritoneal surfaces should be performed. The location of any suspected metastatic disease should be documented in the operative report and a biopsy should be performed to confirm the diagnosis. If intraperitoneal disease is detected, the radical hysterectomy should be abandoned. In patients with macroscopic evidence of metastatic disease to the lymph nodes, intraoperative frozen section should be performed to confirm the presence of metastatic disease. Intraoperative management will be left to the discretion of the surgeon. Patients who have confirmed macroscopic lymph node metastases intraoperatively will be excluded from final analysis and replaced due to the controversy surrounding the decision to perform a radical hysterectomy in this setting. Patients in whom the hysterectomy is abandoned will be deemed non-evaluable and excluded from final analysis and will be replaced. For all patients, the surgeon should document operative time from incision to close, detailed description of operative findings, intraoperative complications, and blood loss. For patients randomized to the robotic arm, the surgeon should document the use of and specify the type of vaginal manipulator and the reason for conversion to laparotomy (if applicable). Transcervical manipulators are not permitted.
Standard arm: Radical or simple hysterectomy is performed as per standard technique (peon radical hysterectomy (Piver type 2 or 3 or Querleu \& Morrow Type B or C) with salpingectomy +/- oophorectomy. Ovaries may be removed or preserved +/- transposition. Prior to colpotomy, the vagina must be closed over the tumor (ie, Wertheim clamps, contour stapling device).
Study arm: Radical or simple hysterectomy is performed as per standard robotic technique (Querleu \& Morrow Type B or C) with salpingectomy +/- oophorectomy. Ovaries may be removed or preserved +/- transposition. Colpotomy may be made intracorporally or vaginally. Vagina must be closed prior to intracorporeal colpotomy (see below, #10)
- Conditions
- Cervical Cancer
- Being tested
- da Vinci, open surgery
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
da VinciDevice
Minimally invasive robotic-assisted radical or simple hysterectomy
open surgeryOther
open radical or simple hysterectomy
| Study group | Role | What they receive |
|---|---|---|
| Open radical or simple hysterectomy | Active comparator | Not described Receives: Other: open surgery |
| Robotic radical or simple hysterectomy | Experimental | Not described Receives: Device: da Vinci |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival
3 year disease-free survival
Measured: 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2021
- Study start22 Mar 2022
- Primary completionMar 2029 (estimated)
- Study completionMar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cervical CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 840 participants (estimated)
Sponsor and investigators
- Lead sponsor
- GOG Foundation
- Sponsor type
- Research network
- Collaborators
- Intuitive Foundation
- Responsible party
- Sponsor
- Investigators
- Kristin Bixel, MD, Study chair, Standford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04831580
- Sponsor's protocol ID
- GOG-3043
- Acronym
- ROCC
- Status last verified
- Jul 2026
- First submitted
- 1 Apr 2021
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Publications
Leitao MM Jr, Bixel KL, Chase DM, Quick A, McCormick C, Black D, Lim PC, Eskander RN, Gotlieb WH, LoCoco S, Martino MA, Walker JL, Copeland LJ, Monk BJ, Randall LM. ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer. Int J Gynecol Cancer. 2025 Jul;35(7):101760. doi: 10.1016/j.ijgc.2025.101760. Epub 2025 Feb 28.
PubMed 40188007Boisen M, Guido R. Emerging Treatment Options for Cervical Dysplasia and Early Cervical Cancer. Clin Obstet Gynecol. 2023 Sep 1;66(3):500-515. doi: 10.1097/GRF.0000000000000790. Epub 2023 Jul 25.
PubMed 37650664
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of Robotic Versus Open Surgery for Early Stage Cervical Cancer (ROCC)
- ClinicalTrials.gov ID
- NCT04831580
- Acronym / sponsor ID
- ROCC / GOG-3043
- Conditions
- Cervical Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 840 participants (estimated)
- Lead sponsor
- GOG FoundationResearch network
- Collaborators
- Intuitive Foundation
- Study start
- 22 Mar 2022 (actual)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Mar 2030 (estimated)
- First posted
- 5 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Detailed description
This is a multi-center, open-label, randomized, non-inferiority clinical trial with the hypothesis that robotically assisted hysterectomy with tumor containment prior to colpotomy is non-inferior to abdominal hysterectomy with respect to disease free survival.
At the commencement of surgery, a thorough inspection of all peritoneal surfaces should be performed. The location of any suspected metastatic disease should be documented in the operative report and a biopsy should be performed to confirm the diagnosis. If intraperitoneal disease is detected, the radical hysterectomy should be abandoned. In patients with macroscopic evidence of metastatic disease to the lymph nodes, intraoperative frozen section should be performed to confirm the presence of metastatic disease. Intraoperative management will be left to the discretion of the surgeon. Patients who have confirmed macroscopic lymph node metastases intraoperatively will be excluded from final analysis and replaced due to the controversy surrounding the decision to perform a radical hysterectomy in this setting. Patients in whom the hysterectomy is abandoned will be deemed non-evaluable and excluded from final analysis and will be replaced. For all patients, the surgeon should document operative time from incision to close, detailed description of operative findings, intraoperative complications, and blood loss. For patients randomized to the robotic arm, the surgeon should document the use of and specify the type of vaginal manipulator and the reason for conversion to laparotomy (if applicable). Transcervical manipulators are not permitted.
Standard arm: Radical or simple hysterectomy is performed as per standard technique (peon radical hysterectomy (Piver type 2 or 3 or Querleu \& Morrow Type B or C) with salpingectomy +/- oophorectomy. Ovaries may be removed or preserved +/- transposition. Prior to colpotomy, the vagina must be closed over the tumor (ie, Wertheim clamps, contour stapling device).
Study arm: Radical or simple hysterectomy is performed as per standard robotic technique (Querleu \& Morrow Type B or C) with salpingectomy +/- oophorectomy. Ovaries may be removed or preserved +/- transposition. Colpotomy may be made intracorporally or vaginally. Vagina must be closed prior to intracorporeal colpotomy (see below, #10)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Open radical or simple hysterectomy | Active comparator | Other: open surgery |
| Robotic radical or simple hysterectomy | Experimental | Device: da Vinci |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Patient must have histologically confirmed adenocarcinoma (usual/classic/NOS), squamous cell carcinoma, adenosquamous carcinoma (Including glassy cell)
- Patient must be FIGO Stage IA2, IBI, IB2 (2018 staging) without evidence of definitive parametrial, vaginal, nodal or distant metastases on exam or imaging. Patients with tumor size less than or equal to 4 cm confirmed on MRI prior to randomization are eligible.
- Patient must have uterine size <12 cm AND felt to be appropriate for vaginal delivery of the specimen per investigator.
- Patient must be suitable surgical candidate with preoperative assessments such as labs and EKG performed per institutional standard and agree to be randomized to undergo open or robotic radical (or simple) hysterectomy.
- Submission of source documents in the GOG Partners Source Document Portal will be required prior to randomization for review and confirmation of simple hysterectomy being met (see Section 6.0 for instructions).
Key exclusion criteria (10 listed)
- Patients with any tumor histology other than those listed above, specifically excluding the following histologies: neuroendocrine, other adenocarcinoma (gastric type, endometrioid, clear cell, serous, signet ring, minimal deviation)
- Patients with FIGO stage 1A1, IB3, II-IV (2018 staging).
- Patient with inability to receive an MRI.
- Patients with a tumor size greater than 4cm or on MRI confirmed prior to randomization are excluded. Patients with definite evidence of vaginal/parametrial involvement on MRI are excluded; if MRI findings are not definitive, then clinical examination must also not reveal parametrial or vaginal extension).
- Patients with evidence of metastatic disease (imaging or histologically positive lymph nodes).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| da VinciMinimally invasive robotic-assisted radical or simple hysterectomy | Device | Robotic radical or simple hysterectomy |
| open surgeryopen radical or simple hysterectomy | Other | Open radical or simple hysterectomy |
Primary outcome
Survival
Time frame: 36 months
3 year disease-free survival
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- Derived from this study: PubMed 40188007Leitao MM Jr, Bixel KL, Chase DM, Quick A, McCormick C, Black D, Lim PC, Eskander RN, Gotlieb WH, LoCoco S, Martino MA, Walker JL, Copeland LJ, Monk BJ, Randall LM. ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer. Int J Gynecol Cancer. 2025 Jul;35(7):101760. doi: 10.1016/j.ijgc.2025.101760. Epub 2025 Feb 28.
- Derived from this study: PubMed 37650664Boisen M, Guido R. Emerging Treatment Options for Cervical Dysplasia and Early Cervical Cancer. Clin Obstet Gynecol. 2023 Sep 1;66(3):500-515. doi: 10.1097/GRF.0000000000000790. Epub 2023 Jul 25.
- Individual participant dataSharing planned: Undecided
Related trials for Cervical Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kristin Bixel, MD study chair
Standford University
156 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing da Vinci and open surgery in people with Cervical Cancer, run by GOG Foundation at 156 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 156 sites in United States, South Korea, Brazil, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sarin Chhab (215-854-0770, schhab@gog.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival (time frame: 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04831580, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.